MedTrace Logo

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

NCT00735332 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2010-08-05

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy and safety of TLN-232 used to treat patients with metastatic melanoma that recur/progress after receiving first line systemic therapy.

Conditions

Interventions

DRUG

TLN-232

21 day continuous IV administration of TLN-232 followed by a 7-day recovery period

Sponsors & Collaborators

  • Thallion Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • David Hogg, MD · Princess Margaret Hospital, Toronto

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-12-31
Completion
2010-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00735332 on ClinicalTrials.gov